Recent advances in peptide-based therapies for obesity and type 2 diabetes

Keyphrases

• A1 Receptor 25%
• Amylin Analogues 25%
• Blood Glucose 25%
• Cagrilintide 25%
• Cardioprotection 25%
• Clinical Trials 25%
• Control Body 25%
• Dual Agonist 25%
• Early Clinical Development 25%
• Gastrointestinal Side Effects 25%
• Glucagon-like 75%
• Glucagon-like peptide-1 Receptor (GLP-1R) 25%
• Glucose-dependent Insulinotropic Polypeptide 50%
• Glycated Hemoglobin A1c 25%
• High Dose 25%
• Incretin 75%
• Incretin-based Therapy 25%
• Moderate to Severe 25%
• Non-diabetic Obese 25%
• Obese Men 25%
• Obesity 100%
• Once-daily 25%
• Once-weekly 50%
• Peptide Drugs 75%
• Peptide-based Therapeutics 100%
• Recent Advances 100%
• Receptor Agonist 25%
• Renoprotective Effect 25%
• Semaglutide 50%
• Subcutaneous Injection 25%
• Tirzepatide 25%
• Treatment Cessation 25%
• Type 2 Diabetes Mellitus (T2DM) 100%
• Type 2 Diabetes Prevention 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Amylin Derivative 25%
• Clinical Trial 25%
• Diabetic Obesity 25%
• Gastric Inhibitory Polypeptide 50%
• Glucagon Like Peptide 1 Receptor Agonist 25%
• Glucagon Receptor Agonist 25%
• Glucagon-Like Peptide-1 50%
• Glycosylated Hemoglobin 25%
• Hemoglobin A1c 25%
• Incretin 100%
• Non Insulin Dependent Diabetes Mellitus 100%
• Receptor 25%
• Semaglutide 50%
• Subcutaneous Injection 25%
• Tablet 25%
• Tirzepatide 25%

Neuroscience

• Agonist 25%
• Amylin Derivative 25%
• Diabetes Mellitus 100%
• Gastric Inhibitory Polypeptide 50%
• Glucagon Receptor 25%
• Glucagon-Like Peptide-1 50%
• Glucagon-Like Peptide-1 Agonist 25%
• Glycosylated Hemoglobin 25%
• Hemoglobin A1c 25%
• Incretin 100%
• Receptor 25%
• Receptor Agonists 25%
• Semaglutide 50%
• Tirzepatide 25%